Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

<p>Supplementary Table S7. DEGs for 1 month Comparison of CD49d+ and CD49d-</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Anfal Alsadhan (15907475) (author)
Бусад зохиолчид:	Jonathan Chen (15907478) (author), Erika M. Gaglione (15032498) (author), Chingiz Underbayev (15907481) (author), Pamela L. Tuma (15907484) (author), Xin Tian (15907487) (author), Lita A. Freeman (15907490) (author), Sivasubramanian Baskar (15907493) (author), Pia Nierman (15907496) (author), Susan Soto (15907499) (author), Andy Itsara (15907502) (author), Inhye E. Ahn (15032501) (author), Clare Sun (14953020) (author), Elena Bibikova (15907505) (author), Tanja Nicole Hartmann (15907508) (author), Maissa Mhibik (15907511) (author), Adrian Wiestner (15907514) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Immuno-oncology Cell Signaling Cell adhesion Protein tyrosine kinases Drug Resistance Hematological Cancers Leukemias Lymphomas Immunology Immunomodulation
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Table S10 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
-н: Anfal Alsadhan (15907475)
Хэвлэсэн: (2025)

Supplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
-н: Anfal Alsadhan (15907475)
Хэвлэсэн: (2025)

Supplementary Table S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
-н: Anfal Alsadhan (15907475)
Хэвлэсэн: (2025)

Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
-н: Anfal Alsadhan (15907475)
Хэвлэсэн: (2025)

Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
-н: Anfal Alsadhan (15907475)
Хэвлэсэн: (2025)

Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
-н: Anfal Alsadhan (15907475)
Хэвлэсэн: (2025)

Table S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
-н: Zhihang Chen (17315678)
Хэвлэсэн: (2025)

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC.docx
-н: Xinhang Gu (22686224)
Хэвлэсэн: (2025)

Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
-н: Ruth Flümann (15123900)
Хэвлэсэн: (2025)

Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
-н: Ruth Flümann (15123900)
Хэвлэсэн: (2025)

Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
-н: Ruth Flümann (15123900)
Хэвлэсэн: (2025)

Table S4 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
-н: Ruth Flümann (15123900)
Хэвлэсэн: (2025)

Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
-н: Ruth Flümann (15123900)
Хэвлэсэн: (2025)

Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
-н: Ruth Flümann (15123900)
Хэвлэсэн: (2025)

Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8<sup>+</sup> T Cells
-н: Snehanshu Chowdhury (14957031)
Хэвлэсэн: (2025)

Figure S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
-н: Upendra Kumar Soni (15051683)
Хэвлэсэн: (2025)

Figure S2 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
-н: Upendra Kumar Soni (15051683)
Хэвлэсэн: (2025)

Figure S3 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
-н: Upendra Kumar Soni (15051683)
Хэвлэсэн: (2025)

Figure S4 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
-н: Upendra Kumar Soni (15051683)
Хэвлэсэн: (2025)

Figure S5 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
-н: Upendra Kumar Soni (15051683)
Хэвлэсэн: (2025)

Figure S6 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
-н: Upendra Kumar Soni (15051683)
Хэвлэсэн: (2025)

Supplementary Data File S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
-н: Upendra Kumar Soni (15051683)
Хэвлэсэн: (2025)

Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
-н: Ti Wen (15130158)
Хэвлэсэн: (2025)

Supplementary Table S1 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
-н: Nan Ding (15321526)
Хэвлэсэн: (2025)

Supplementary Table S2 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
-н: Nan Ding (15321526)
Хэвлэсэн: (2025)

Filamin A KO and S2152A KI reduce KSHV de novo infection of cell-free virions.
-н: Xiaojuan Li (351842)
Хэвлэсэн: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
-н: Erika Y. Faraoni (14844897)
Хэвлэсэн: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
-н: Erika Y. Faraoni (14844897)
Хэвлэсэн: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
-н: Erika Y. Faraoni (14844897)
Хэвлэсэн: (2025)

Supplementary Tables from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
-н: Francesco Maura (15022226)
Хэвлэсэн: (2025)

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
-н: Ernesto Gargiulo (15134961)
Хэвлэсэн: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
-н: Ernesto Gargiulo (15134961)
Хэвлэсэн: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
-н: Ernesto Gargiulo (15134961)
Хэвлэсэн: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
-н: Ernesto Gargiulo (15134961)
Хэвлэсэн: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
-н: Ernesto Gargiulo (15134961)
Хэвлэсэн: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
-н: Ernesto Gargiulo (15134961)
Хэвлэсэн: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
-н: Ernesto Gargiulo (15134961)
Хэвлэсэн: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
-н: Jonathan M.J. Derry (16648337)
Хэвлэсэн: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
-н: Jonathan M.J. Derry (16648337)
Хэвлэсэн: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
-н: Jonathan M.J. Derry (16648337)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_4nue0u4q2s8murv161doe9m3me